RXRX — Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.

Sector

Healthcare

Industry

Biotechnology

Market Cap

$1.67B

P/E Ratio

-3.05

Beta

1.01

52-Week Range

2.8-7.18

Dividend Yield

$0.00

CEO

Najat Khan

Employees

800

IPO Date

Apr 16, 2021

Exchange

NASDAQ